What is United Therapeutics's SG&A?

United Therapeutics (UTHR) reported SG&A of $184.1M in Q1 2026.

How has United Therapeutics's SG&A changed year-over-year?

United Therapeutics's SG&A increased by 8.2% year-over-year, from $170.1M to $184.1M.

What is the long-term trend for United Therapeutics's SG&A?

Over 4 years (2021 to 2025), United Therapeutics's SG&A has grown at a 12.8% compound annual growth rate (CAGR), from $467M to $755.8M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

United Therapeutics UTHR SG&A

SG&A at other companies

Johnson & JohnsonJNJ

$6.43B+9.2%

Merck & Co.MRK

$2.7B+5.8%

InsmedINSM

$247.26M+67.6%

LQD

Liquidia CorporationLQDA

$46.94M+56.1%

AmgenAMGN

$1.6B-5.0%

Theravance BiopharmaTBPH

$17.72M-3.5%

Other financials

Income statement

See full

Revenue$781.5M-1.6%

Gross profit$648.1M-7.7%

Operating income$325.8M-14.9%

Net income$274.9M-14.7%

EPS (diluted)$5.82-12.2%

Balance sheet

See full

Cash & equivalents$1.3B-32.6%

Total debt$12.2M—

Total equity$5.9B-13.3%

Total assets$6.7B-13.3%

Cash flow

See full

Operating cash flow$463.3M+0.5%

CapEx$100.8M+34.6%

Free cash flow$362.5M-6.2%

Valuation

See full

Market cap$26.32B+95.7%

P/E20.4×+9.6×

P/S8.3×+3.9×

Profitability

See full

Gross margin86.6%-2.4pp

Operating margin45.3%-1.6pp

Net margin40.6%+0.2pp

FCF margin32.1%-5.6pp

Returns & leverage

See full

Return on equity20.3%+0.3pp

Debt / equity0×—

Current ratio4.8×-0.7×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about United Therapeutics's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is United Therapeutics's SG&A?: United Therapeutics (UTHR) reported SG&A of $184.1M in Q1 2026.
How has United Therapeutics's SG&A changed year-over-year?: United Therapeutics's SG&A increased by 8.2% year-over-year, from $170.1M to $184.1M.
What is the long-term trend for United Therapeutics's SG&A?: Over 4 years (2021 to 2025), United Therapeutics's SG&A has grown at a 12.8% compound annual growth rate (CAGR), from $467M to $755.8M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.